Результаты поиска

Comorbidity of uveitis and multiple sclerosis.

BACKGROUND: The comorbidity of uveitis and multiple sclerosis (MS) is recognized but reported prevalence rates vary. We aimed to investigate the prevalence and characteristics of uveitis in people with multiple sclerosis (pwMS) in Finland by conducting a prospective screening study. METHODS: pwMS 18-60 years of age were identified from the Finnish MS registry in Tampere University Hospital, Finland. Identified pwMS who were capable of independently attend an ocular examination were invited for a comprehensive uveitis screening examination. RESULTS: In total 22 of 344 (6 %) of pwMS had uveiti…

Роль сна в множественном склерозе.

Множественный склероз (MS) — расстройство, связанное с автоматическим иммунитетом и затрагивающее главным образом молодых людей. Высокая распространенность этого заболевания и его воздействие на качество жизни пациентов побудили исследователей изучить этиопатогенез этого заболевания для выявления возможных модифицируемых факторов и соответствующих эффективных стратегий вмешательства. Недавние гипотезы говорят о том, что этиопатогенез MS является многофакторным и включает в себя факторы, связанные с иммунной системой, нейроинфламмацией и нейродегенерацией. В этом сценарии сон, как представляетс

Совпадение в аннотации оригинала
Multiple Sclerosis (MS) is an autoimmunity-related disorder that mainly affects young adults. The high prevalence of the disease and its impact on patients' quality of life led researchers to investigate the etiopathogenesis of the disease to identify possible modifiable factors and consequent effective intervention strategies. Recent hypotheses suggest that…

Роль изофлавонов в множественном склерозе.

Myelin дегенерация является отличительной чертой множественного склероза, хронического, аутоиммунного неврологического состояния, которое изменяет связь с центральной нервной системой. Несмотря на тот факт, что патофизиология множественного склероза является многофакторной и не вполне понятной, новые исследования показывают, что уменьшение окислительного стресса и воспаления может иметь терапевтические преимущества. Класс фитоэстрогенов, называемый изофалонами, которые в основном присутствуют в соях и других бобовых, вызвал интерес из-за их возможных противовоспалительных и нейрозащитных свойс

Совпадение в аннотации оригинала
Myelin degeneration is a hallmark of multiple sclerosis, a chronic, autoimmune neurological condition that alters Central Nervous System communication. Despite the fact that the pathophysiology of multiple sclerosis is multifactorial and not fully understood, new research indicates that reducing oxidative stress and inflammation may have therapeutic advantag…

The Burden of Multiple Sclerosis in Mexico.

BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is a CNS disease causing significant disability, mainly in young and middle-aged individuals. Despite extensive global research, Mexico lacks comprehensive epidemiologic data on MS, complicating effective health care planning and intervention. This study analyzes the epidemiology of MS in Mexico using data from the Global Burden of Disease (GBD) study. It focuses on prevalence, incidence, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) from 1990 to 2021. In addition, it examines the rel…

Rituximab for people with multiple sclerosis.

BACKGROUND: Multiple sclerosis (MS) is the most common neurological cause of disability in young adults. Off-label rituximab for MS is used in most countries surveyed by the International Federation of MS, including high-income countries where on-label disease-modifying treatments (DMTs) are available. This updates the 2021 version of the review. OBJECTIVES: To assess the benefits and harms of rituximab as 'first choice' and 'switching' treatment for adults with any form of MS. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, CINAHL, and three trials registers on 31 December 2023, toget…

Прогресс в нейроимизации множественных склерозов.

ЦЕЛЬ ОБЗОРА: Обобщение последних достижений в понимании патофизиологии множественных склерозов (MS), прогнозировании заболеваний и мониторинге реакции на лечение с использованием МРТ. ПОСЛЕДНИЕ ВЫВОДЫ: Повреждения парамагнитных ободов (ПЗК) весьма специфичны для MS и клинически актуальны. Обнаруженные с самых ранних стадий болезни, ПНР помогают отличать МУ от других заболеваний, повышая диагностическую точность. Кроме того, ПБД связаны с более серьезной инвалидностью и показателями повреждения мозга и могут предсказывать прогрессирование заболеваний. Аналогичным образом медленно расширяющиеся

Совпадение в аннотации оригинала
PURPOSE OF REVIEW: To summarize recent advancements in understanding multiple sclerosis (MS) pathophysiology, predicting disease course, and monitoring treatment responses using MRI. RECENT FINDINGS: Paramagnetic rim lesions (PRLs) are highly specific to MS and clinically relevant. Detected from the earliest disease phases, PRLs aid in distinguishing MS fro…

Унификация модели множественного склероза.

Множественный склероз (MS) представляет собой сложное нейродегенеративное расстройство с неразрешенной причиной, ставшей предметом интенсивных исследований. Для разъяснения курса болезни были предложены различные предлагаемые модели. Первостепенные механизмы, как предполагается, основываются на автоматическом иммунитете, в том числе с помощью вирусного имитации эпитопов, хотя и были описаны трудности с классической моделью автономного иммунитета для MS. Одна предыдущая идея, которая включает в себя рассмотрение вирусной самореактивности, заключается в том, что реактивированный вирус HHV-6A мож

Совпадение в аннотации оригинала
Multiple sclerosis (MS) is a complex neurodegenerative disorder with unresolved cause that has been the subject of intensive research. A variety of putative models have been proposed to explain the course of disease. The preeminent mechanisms are suggested to be based on autoimmunity, including via viral epitope mimicry, although difficulties with a classica…

Azathioprine for people with multiple sclerosis.

BackgroundMultiple sclerosis (MS) is an immune-mediated, chronic, inflammatory demyelinating disease of the central nervous system, impacting around 2.8 million people worldwide. Characterised by recurrent relapses or progression, or both, it represents a substantial global health burden, affecting people, predominantly women, at a young age (the mean age of diagnosis is 32 years). Azathioprine is used to treat chronic inflammatory and autoimmune diseases, and it is used in clinical practice as an off-label intervention for MS, especially where access to on-label disease-modifying treatments (…

[Mechanisms of Neurodegeneration in Multiple Sclerosis].

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, which results in the formation of primary demyelinating lesions in the white and gray matter, as well as diffuse axonal and neuronal damage. Although there has been substantial progress in drug research in relapsing-remitting MS, treatment of progressive forms of the disease, can be challenging. Diffuse and compartmentalized lymphocyte and macrophage infiltration of the CNS tissue inhibits the differentiation of myelinating mature oligodendrocytes, disrupting the process of remyelination. Chronic inflammat…

Breastfeeding and treatment for multiple sclerosis.

Monoclonal antibody therapy is effective for multiple sclerosis, and only small amounts of antibodies are transferred to breast milk. Even though the approved product descriptions advise against breastfeeding during medicinal treatment, several of the most effective MS drugs are compatible with breastfeeding.

Rituximab for people with multiple sclerosis.

BackgroundMultiple sclerosis (MS) is the most common neurological cause of disability in young adults. Off-label rituximab for MS is used in most countries surveyed by the International Federation of MS, including high-income countries where on-label disease-modifying treatments (DMTs) are available. OBJECTIVES: To assess beneficial and adverse effects of rituximab as 'first choice' and as 'switching' for adults with MS.Search methodsWe searched CENTRAL, MEDLINE, Embase, CINAHL, and trial registers for completed and ongoing studies on 31 January 2021.Selection criteriaWe included randomised co…

Rehabilitation in multiple sclerosis in 2021.

Patients with multiple sclerosis, despite advances in therapy, often suffer from locomotor impairment that limits their mobility and affect quality of life. Rehabilitation is part of the treatment of MS and has shown its beneficial effects in numerous studies. While traditional rehabilitation techniques remain in the limelight, new technologies are emerging and make it possible to improve the management of disabling symptoms. The aim of this update is to synthesize the new therapy techniques proposed in rehabilitation for patients with multiple sclerosis according to the symptoms as balance, g…

Disorders of vision in multiple sclerosis.

Multiple sclerosis (MS) is a neurological inflammatory disorder known to attack the heavily myelinated regions of the nervous system including the optic nerves, cerebellum, brainstem and spinal cord. This review will discuss the clinical manifestations and investigations for MS and other similar neurological inflammatory disorders affecting vision, as well as the effects of MS treatments on vision. Assessment of visual pathways is critical, considering MS can involve multiple components of the visual pathway, including optic nerves, uvea, retina and occipital cortex. Optical coherence tomograp…

The role of melatonin in Multiple Sclerosis.

Melatonin is a neurohormone mainly produced by the pineal gland following a circadian rhythm. It is characterized as a pleiotropic factor because it not only regulates the wake-sleep rhythm but also exerts antinociceptive, antidepressant, anxiolytic, and immunomodulating properties. Recent studies suggest that dysregulation of melatonin secretion is associated with the pathogenesis of various autoimmune diseases, such as, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). MS is an autoimmune disorder characterized by an abnormal immune response directed…

Siponimod in the treatment of multiple sclerosis.

Introduction: Multiple sclerosis (MS) causes focal lesions of immune-mediated demyelinating events followed by slow progressive accumulation of disability. Over the past 2 decades, multiple medications have been studied and approved for use in MS. Most of these agents work by modulating or suppressing the peripheral immune system. Siponimod is a newer-generation sphingosine 1 phosphate (S1P) receptor modulator that internalizes S1P1 receptors, thereby inhibiting efflux of lymphocytes from lymph nodes and thymus. There are promising data suggesting that it may also have a direct neuroprotective…

Nocturia in Patients With Multiple Sclerosis.

The prevalence of nocturia in patients with multiple sclerosis (MS) is high, ranging from 20.9% to 48.8% in this population. Its underlying pathophysiology is complex and different from the non-neurogenic population. In the MS population, the pathophysiology may involve neurogenic lower urinary tract dysfunction (NLUTD) such as detrusor overactivity (NDO), detrusor-sphincter dyssynergia, or detrusor underactivity resulting in reduced bladder capacity. Nocturnal polyuria is also a significant contributor to the pathogenesis of nocturia in MS patients and may be the result of specific mechanisms…

The role of infections in multiple sclerosis.

Several lines of evidence suggest that multiple sclerosis (MS), like other autoimmune diseases, may be triggered by microbial infections. Pathogens associated with development or exacerbation of MS include bacteria, such as Chlamydia pneumoniae, Staphylococcus aureus-produced enterotoxins that function as superantigens, and viruses of the Herpesviridae (Epstein-Barr virus and human herpes virus 6) and human endogenous retrovirus families. However, to date, no single pathogen has been accepted as causal agent. In addition, common upper respiratory, gastrointestinal, and urogenital tract infecti…

Использование натализумаба для многократного склероза.

Натальизумаб является моноколональным антителом, который действует как α4-интегринский антагонист, чтобы предотвратить торговлю лейкоцитами в центральную нервную систему. Управление по контролю за продуктами питания и лекарственными препаратами США (АПП) одобрило лечение повторно излучаемого многообразного склероза (РРМС). Натальизумаб продемонстрировал высокую эффективность в ходе испытаний на этапе III, уменьшив годовой коэффициент рецидива, предотвратив аккумулирование множественных склерозов (MS) на магнитных резонансных изображениях и снижая вероятность устойчивого развития инвалидности.

Совпадение в аннотации оригинала
Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab demonstrated high efficacy in Phase III trials by reducing the annualized relapse rat…